Marshall Wace’s Beam Therapeutics BEAM Stock Holding History

Marshall Wace’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$16.4M	Buy	478,980 +339,739	+244%	+$10.3M	0.01%	810
2026 Q1	$3.32M	Sell	139,241 -806,588	-85%	-$22.4M	﹤0.01%	1518
2025 Q4	$26.2M	Buy	+945,829	New	+$24.1M	0.02%	543
2025 Q3	–	Sell	-99,959	Closed	-$1.7M	–	2895
2025 Q2	$1.7M	Sell	99,959 -169,170	-63%	-$2.95M	﹤0.01%	1637
2025 Q1	$5.26M	Buy	269,129 +214,129	+389%	+$5.61M	0.01%	1039
2024 Q4	$1.36M	Buy	+55,000	New	+$1.4M	﹤0.01%	1589
2022 Q2	–	Sell	-68,797	Closed	-$3.94M	–	3420
2022 Q1	$3.94M	Sell	68,797 -56,196	-45%	-$3.69M	0.01%	1564
2021 Q4	$9.96M	Buy	+124,993	New	+$10.7M	0.02%	869

Other funds holding BEAM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Marshall Wace's BEAM Position: Q2 2026 in Review

Marshall Wace increased its Beam Therapeutics (BEAM) stake by 244% in Q2 2026, buying an estimated $10.3M and bringing the position to 478,980 shares worth $16.4M. The position accounts for 0.01% of the portfolio, ranked #810.

Marshall Wace first reported a position in BEAM in Q4 2021 and has held it in 8 quarters since. The position peaked at $26.2M in Q4 2025. 277 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

Marshall Wace held 478,980 shares of Beam Therapeutics worth $16.4M as of Q2 2026.
Marshall Wace bought 339,739 Beam Therapeutics shares in Q2 2026, an estimated $10.3M.
Beam Therapeutics made up 0.01% of Marshall Wace's portfolio in Q2 2026, its #810 holding.
Marshall Wace first reported a position in Beam Therapeutics in Q4 2021 and has held it in 8 quarters since.
Marshall Wace's Beam Therapeutics position peaked at $26.2M in Q4 2025.
277 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.